Targeted Oncology38m
CAR T-Cells Demonstrate Efficacy, Tolerability in Early-Relapsed DLBCL
During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...
Targeted Oncology3h
FDA Grants Breakthrough Therapy Status to Petosemtamab/Pembrolizumab in HNSCC
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
Targeted Oncology4h
CRISTALLO Study of Venetoclax/Obinutuzumab Achieves Superior MRD in CLL
The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...
Targeted Oncology8h
Therapeutic options for a patient with mCRPC after ADT + docetaxel
An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...
Targeted Oncology9h
Second-Line Therapy Options
A panelist discusses how second-line treatment options for kidney cancer have evolved through multiple clinical trials ...